| risperidone / Generic mfg. |
NCT00986336: A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders |
|
|
| Completed | 1 | 56 | US | topiramate, risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | | 11/02 | | |
NCT00791232: A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia |
|
|
| Completed | 1 | 113 | US | extended-release (ER) OROS paliperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 06/03 | | |
NCT00645502: Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. |
|
|
| Completed | 1 | 40 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Schizoaffective Disorders | | 07/03 | | |
NCT00796185: As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations |
|
|
| Completed | 1 | 62 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Schizoaffective Disorder | | 01/04 | | |
NCT00364429: SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia |
|
|
| Terminated | 1 | 55 | Europe | [123]I-CNS 1261, Lorazepam, Risperidone | GlaxoSmithKline | Schizophrenia | 07/05 | 07/05 | | |
NCT00269035: SPECT Study With SB-773812 In Schizophrenic Patients |
|
|
| Completed | 1 | 95 | Europe | SB773812, Risperidone | GlaxoSmithKline | Schizophrenia | 05/07 | 05/07 | | |
NCT00500201: A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets. |
|
|
| Completed | 1 | 18 | Europe | SB- 773812 60 mg, SB- 773812, SB- 773812 120 mg, Placebo | GlaxoSmithKline | Schizophrenia | 07/07 | 07/07 | | |
NCT00411866: Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812 |
|
|
| Completed | 1 | 36 | Europe | SB773812, Ketoconazole | GlaxoSmithKline | Schizophrenia | 10/07 | 10/07 | | |
NCT00466310: Metabolic Signatures and Biomarkers in Schizophrenia |
|
|
| Completed | 1 | 71 | US | Aripiprazole, Abilify, Risperidone, Risperdal, Healthy volunteers | Duke University, Bristol-Myers Squibb | Schizophrenia | 01/09 | 01/11 | | |
| Completed | 1 | 60 | US | SB773812 | GlaxoSmithKline | Schizophrenia | | | | |
NCT00821600: Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia |
|
|
| Completed | 1 | 24 | US | risperidone IR and LAI formulation | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Psychotic Disorders, Schizophrenia | 06/09 | 06/09 | | |
NCT01376076: Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia |
|
|
| Completed | 1 | 129 | US | Cariprazine, Risperidone/Moxifloxacin | Forest Laboratories | Schizophrenia | 02/12 | 02/12 | | |
NCT02019329: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone |
|
|
| Completed | 1 | 32 | US | Placebo, RO5545965, risperidone | Hoffmann-La Roche | Schizophrenia | 08/14 | 08/14 | | |
NCT02087579: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants |
|
|
| Completed | 1 | 305 | US, Europe, RoW | Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, INVEGA®, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, RISPERDAL®, Risperidone, LAI | Janssen Research & Development, LLC | Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder | 10/14 | 12/14 | | |
